Lenore J. Launer

Lenore J. Launer

Auto-generated profile, based on publicly available information

Lenore J. Launer

Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Baltimore, MD (L.J.L.).

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2022 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CBCéline Bellenguez
Céline Bellenguez
FKFahri Küçükali
Fahri Küçükali
IJIris E. Jansen
Iris E. Jansen
LKLuca Kleineidam
Luca Kleineidam
SMSonia Moreno-Grau
Sonia Moreno-Grau
JLJean-Charles Lambert
Jean-Charles Lambert
Characterization of the genetic landscape of Alzheimer’s disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/‘proxy’ AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele.

9 December 2021 in Nature
Verified
Journal Article
Closed access
PDF file
SGSarah E. Graham
Sarah E. Graham
SCShoa L. Clarke
Shoa L. Clarke
KWKuan-Han H. Wu
Kuan-Han H. Wu
Stavroula KanoniStavroula Kanoni
Stavroula Kanoni
GZGreg J. M. Zajac
Greg J. M. Zajac
CWCristen J. Willer
Cristen J. Willer

23 July 2002 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
RSReinhold Schmidt
Reinhold Schmidt
HSHelena Schmidt
Helena Schmidt
JCJ. David Curb
J. David Curb
KMKamal Masaki
Kamal Masaki
LWLon R. White
Lon R. White
LLLenore J. Launer
Lenore J. Launer

30 September 2022 in Nature
Verified
Journal Article
Open access
PDF file
AMAniket Mishra
Aniket Mishra
RMRainer Malik
Rainer Malik
THTsuyoshi Hachiya
Tsuyoshi Hachiya
TJTuuli Jürgenson
Tuuli Jürgenson
SNShinichi Namba
Shinichi Namba
SDStephanie Debette
Stephanie Debette
Previous genome-wide association studies (GWASs) of stroke — the second leading cause of death worldwide — were conducted predominantly in populations of European ancestry1,2. Here, in cross-ancestry GWAS meta-analyses of 110,182 patients who have had a stroke (five ancestries, 33% non-European) and 1,503,898 control individuals, we identify association signals for stroke and its subtypes at 89 (61 new) independent loci: 60 in primary inverse-variance-weighted analyses and 29 in secondary meta-regression and multitrait analyses. On the basis of internal cross-ancestry validation and an independent follow-up in 89,084 additional cases of stroke (30% non-European) and 1,013,843 control individuals, 87% of the primary stroke risk loci and 60% of the secondary stroke risk loci were replicated (P < 0.05). Effect sizes were highly correlated across ancestries. Cross-ancestry fine-mapping, in silico mutagenesis analysis3, and transcriptome-wide and proteome-wide association analyses revealed putative causal genes (such as SH3PXD2A and FURIN) and variants (such as at GRK5 and NOS3). Using a three-pronged approach4, we provide genetic evidence for putative drug effects, highlighting F11, KLKB1, PROC, GP1BA, LAMC2 and VCAM1 as possible targets, with drugs already under investigation for stroke for F11 and PROC. A polygenic score integrating cross-ancestry and ancestry-specific stroke GWASs with vascular-risk factor GWASs (integrative polygenic scores) strongly predicted ischaemic stroke in populations of European, East Asian and African ancestry5. Stroke genetic risk scores were predictive of ischaemic stroke independent of clinical risk factors in 52,600 clinical-trial participants with cardiometabolic disease. Our results provide insights to inform biology, reveal potential drug targets and derive genetic risk prediction tools across ancestries.

25 June 2008 in JAMA
Verified
Journal Article
Open access
PDF file
HBHans Tomas Bjornsson
Hans Tomas Bjornsson
MSMartin I. Sigurdsson
Martin I. Sigurdsson
MFM. Daniele Fallin
M. Daniele Fallin
RIRafael A. Irizarry
Rafael A. Irizarry
TAThor Aspelund
Thor Aspelund
AFAndrew P. Feinberg
Andrew P. Feinberg
Epigenetic marks are modifications of DNA or associated proteins, other than the DNA sequence itself, that are heritable through cell division. These include DNA methylation, a covalent modification of cytosine; histone modifications affecting the nucleosomes around which the DNA is coiled; and alterations in nucleosomal packing or higher-order folding of chromatin. We and others have suggested that epigenetics might play a role in the etiology of common human diseases.1-3 In a recent review in JAMA by 1 of us (A.P.F.), it was noted that epigenetics stands at the epicenter of modern medicine because it unites nuclear reprogramming during development, environmentally induced changes on the body, and the ability of cells to respond appropriately to external stimuli.4 That is because epigenetic changes, unlike the DNA sequence, distinguish one tissue type from another and dietary and other environmental exposures alter the epigenetic program; the ability of genes to alter their expression is controlled by epigenetic factors such as DNA methylation.5,6 Diseases in which epigenetic change has been shown to play a major role include cancer and some disorders of the immune system, and epigenetic defects may also contribute to chronic diseases such as diabetes, bipolar disorder, and autism and loss of normal responsiveness to stress that accompanies aging.7-9

1 November 2011 in The Lancet Neurology
Verified
Journal Article
Closed access
LLLenore J Launer
Lenore J Launer
MMMichael E Miller
Michael E Miller
JWJeff D Williamson
Jeff D Williamson
RLRon M Lazar
Ron M Lazar
HGHertzel C Gerstein
Hertzel C Gerstein
RBR Nick Bryan
R Nick Bryan